Researchers have identified a genetic marker strongly associated with severe inflammatory bowel disease (IBD), potentially enabling earlier intervention with advanced therapies. The HLA-DRB1*01:03 variant, present in approximately one in 20 patients, predicts greater need for surgery and biological treatment in both Crohn’s disease and ulcerative colitis.
Background
IBD encompasses Crohn’s disease and ulcerative colitis, chronic inflammatory conditions affecting the gastrointestinal tract. Disease severity varies considerably between individuals, with some patients experiencing mild symptoms controlled by first-line therapies whilst others progress rapidly to complications requiring surgery or advanced biological agents. Predicting which patients will follow a more aggressive disease course has remained a significant clinical challenge. Current treatment pathways typically escalate therapy in response to worsening symptoms rather than proactively identifying high-risk individuals at diagnosis.
Key Findings
A study published in The Lancet Gastroenterology and Hepatology analysed genetic data from more than 43,000 IBD patients and identified a strong association between the HLA-DRB1*01:03 gene variant and severe disease outcomes. Patients carrying this variant demonstrated significantly higher rates of progression to surgery and requirement for advanced biological therapies compared with those without the marker.
The research team also identified a mechanistic explanation for this association. In a parallel study published in the New England Journal of Medicine, investigators found that patients with the HLA-DRB1*01:03 variant are more likely to develop autoantibodies against interleukin-10 (IL-10), a critical anti-inflammatory cytokine that normally suppresses excessive immune responses in the gut. When these neutralising autoantibodies block IL-10 function, the body loses a key regulatory mechanism controlling inflammation, leading to uncontrolled disease activity.
This discovery resolves a question that has puzzled researchers for three decades: how specific genetic variants translate into more severe clinical phenotypes in IBD. The identification of anti-IL-10 autoantibodies provides a clear biological pathway linking genotype to disease severity.
Clinical Relevance
These findings offer a potential framework for risk stratification at or soon after IBD diagnosis. Genetic screening for HLA-DRB1*01:03 could identify patients who would benefit from closer monitoring and earlier escalation to biological therapies, potentially preventing irreversible bowel damage and reducing the need for surgical intervention. The discovery of anti-IL-10 autoantibodies as a disease mechanism also opens possibilities for targeted therapeutic approaches, either by suppressing the immune cells producing these antibodies or by developing agents that bypass the blocked IL-10 pathway. However, translating these research insights into routine clinical practice will require further validation studies and development of accessible, cost-effective genetic testing protocols suitable for National Health Service implementation.
References
Zhang Q, et al. HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study. Lancet Gastroenterol Hepatol. 2026;11(8):660-671. doi:10.1016/S2468-1253(26)00113-5
Chong AY, Anderson CA, et al. Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease. N Engl J Med. 2026;394(22):2212-2222. doi:10.1056/NEJMoa2513654
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.